Company news

Regenxbio Inc. news in 2023

Regenxbio Inc.'s news releases, calls and decks from 2023, newest first.

View company

REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® Trial

November 28, 2023

REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results

November 7, 2023

REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

November 2, 2023

REGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2023 Financial Results and Recent Operational Highlights

October 31, 2023

REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting

October 29, 2023

REGENXBIO to Participate in the Jefferies CNS/Neuro Summit

October 4, 2023

REGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNE™ Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society

October 2, 2023

REGENXBIO Announces Presentations at the 28th Annual Congress of the World Muscle Society

September 25, 2023

Initial Clinical Data of First Pediatric CLN2 Patient Dosed with RGX-181 Presented at SSIEM Annual Symposium

August 29, 2023

REGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023

August 22, 2023

REGENXBIO Reports Second Quarter 2023 Financial Results and Recent Operational Highlights

August 1, 2023

REGENXBIO Announces Participation at the 2023 Wedbush PacGrow Healthcare Conference

July 31, 2023

REGENXBIO to Host Conference Call on August 2 to Discuss Second Quarter 2023 Financial Results and Recent Operational Highlights

July 25, 2023

REGENXBIO Announces Upcoming Presentations at the American Society of Retina Specialists Annual Scientific Meeting

July 23, 2023

REGENXBIO Highlights AAV Pipeline with Interim Results from Retinal and Duchenne Programs at its Virtual Investor Day on July 11, 2023

July 10, 2023

REGENXBIO to Host Virtual Investor Day Highlighting AAV Pipeline Programs with Upcoming Interim Trial Updates

June 26, 2023

REGENXBIO and University of Pennsylvania File NAV® Technology Patent Infringement Lawsuit

June 19, 2023

REGENXBIO Announces Presentation at the Jefferies Global Healthcare Conference

May 31, 2023

REGENXBIO Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RGX-121 Gene Therapy for Hunter Syndrome

May 22, 2023

REGENXBIO Announces Presentation at the Barclays Gene Editing & Therapy Summit 2023

May 21, 2023

REGENXBIO Announces NAV® Technology Platform Will Support Bespoke Gene Therapy Consortium's First Rare Disease Clinical Portfolio

May 15, 2023

REGENXBIO Reports First Quarter 2023 Financial Results and Recent Operational Highlights

May 2, 2023

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 26th Annual Meeting

May 1, 2023

REGENXBIO to Host Conference Call on May 3 to Discuss First Quarter 2023 Financial Results and Recent Operational Highlights

April 25, 2023

REGENXBIO Announces Presentation at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

April 17, 2023

REGENXBIO Receives FDA Fast Track Designation for RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy

April 10, 2023

REGENXBIO Reports Fourth Quarter 2022 and Full-Year 2022 Financial Results and Recent Operational Highlights

February 27, 2023

Additional Positive Interim Data from Phase I/II Trial of REGENXBIO'S RGX-111 for the Treatment of Severe MPS I Presented at WORLDSymposium™

February 23, 2023

Additional Positive Interim Data from Phase I/II/III CAMPSIITE™ Trial of REGENXBIO's RGX-121 for the Treatment of MPS II (Hunter Syndrome) Presented at 19th Annual WORLDSymposiumTM

February 21, 2023

REGENXBIO to Host Conference Call on February 28 to Discuss Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

February 20, 2023

REGENXBIO Announces Presentations at the 19th Annual WORLDSymposium™ 2023

February 16, 2023

REGENXBIO Presents Interim Data from Phase II Bridging Study Evaluating the Clinical Performance of RGX-314 Using the NAVXpress™ Manufacturing Platform Process

February 10, 2023

REGENXBIO Announces Presentation at the Virtual SVB Securities Global Biopharma Conference

February 7, 2023

REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and Degeneration 2023 Conference

February 5, 2023

REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients

January 22, 2023

REGENXBIO announces senior leadership promotions

January 8, 2023

REGENXBIO Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

Calls in 2023

Decks in 2023